Sugawara I, Masunaga A, Itoyama S, Sumizawa T, Akiyama S, Yamashita T
Department of Pathology, Saitama Medical Center, Saitama Medical School, Japan.
Cancer Lett. 1995 Aug 16;95(1-2):135-8. doi: 10.1016/0304-3835(95)03878-z.
It was found that the mechanism of anti-cancer drug resistance in anaplastic carcinoma of the thyroid was not explicable only in terms of expression of mdr1 and its gene product, P-glycoprotein. The multidrug resistance-associated protein (MRP), another member of the mdr gene family, may be involved in anti-cancer drug resistance of this carcinoma. The MRP expression was examined immunohistochemically in 8 cell lines and 73 thyroid cancer tissues; its frequency in anaplastic carcinoma (52%) was significantly higher than that in other thyroid cancer types.
研究发现,甲状腺间变性癌的抗癌耐药机制不能仅用多药耐药基因1(mdr1)及其基因产物P-糖蛋白的表达来解释。mdr基因家族的另一个成员——多药耐药相关蛋白(MRP),可能与该癌症的抗癌耐药性有关。采用免疫组织化学方法检测了8种细胞系和73例甲状腺癌组织中的MRP表达;其在间变性癌中的表达频率(52%)显著高于其他类型的甲状腺癌。